FY2025 Earnings Estimate for ITCI Issued By Leerink Partnrs

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) – Research analysts at Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for Intra-Cellular Therapies in a research note issued on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings of $0.50 per share for the year, down from their previous forecast of $0.55. The consensus estimate for Intra-Cellular Therapies’ current full-year earnings is ($0.59) per share.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. Intra-Cellular Therapies had a negative net margin of 14.93% and a negative return on equity of 11.48%. The business had revenue of $161.40 million for the quarter, compared to analyst estimates of $157.74 million. During the same period last year, the firm posted ($0.45) earnings per share. The company’s revenue for the quarter was up 45.7% compared to the same quarter last year.

ITCI has been the subject of several other research reports. Morgan Stanley increased their target price on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. JPMorgan Chase & Co. increased their price objective on Intra-Cellular Therapies from $79.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Piper Sandler raised Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $68.00 to $92.00 in a report on Friday, September 6th. Mizuho increased their price target on Intra-Cellular Therapies from $96.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, June 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $130.00 price objective on shares of Intra-Cellular Therapies in a research report on Monday, September 16th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $96.62.

Intra-Cellular Therapies Stock Performance

Shares of Intra-Cellular Therapies stock opened at $78.68 on Thursday. The company has a market capitalization of $8.31 billion, a P/E ratio of -67.83 and a beta of 1.00. Intra-Cellular Therapies has a 1 year low of $45.50 and a 1 year high of $84.89. The company’s fifty day moving average is $74.33 and its two-hundred day moving average is $72.38.

Hedge Funds Weigh In On Intra-Cellular Therapies

Several hedge funds have recently bought and sold shares of the stock. Kapitalo Investimentos Ltda acquired a new stake in shares of Intra-Cellular Therapies during the fourth quarter valued at $26,000. Headlands Technologies LLC acquired a new position in shares of Intra-Cellular Therapies in the first quarter valued at approximately $32,000. Fidelis Capital Partners LLC purchased a new position in shares of Intra-Cellular Therapies during the first quarter valued at approximately $53,000. Summit Securities Group LLC acquired a new stake in Intra-Cellular Therapies during the second quarter worth approximately $56,000. Finally, CWM LLC grew its stake in Intra-Cellular Therapies by 83.9% in the 2nd quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 626 shares during the period. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Insider Activity

In related news, CEO Sharon Mates sold 53,013 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total value of $4,010,433.45. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $80,970,388.85. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Intra-Cellular Therapies news, EVP Mark Neumann sold 18,714 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $75.08, for a total value of $1,405,047.12. Following the sale, the executive vice president now owns 29,700 shares of the company’s stock, valued at $2,229,876. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sharon Mates sold 53,013 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at approximately $80,970,388.85. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 175,316 shares of company stock worth $13,037,345. Company insiders own 3.40% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.